Develops modified T-cell treatments for patients with autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis.
10-K for FY2025, filed Mar 26, 2026We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our…View ↗
Miv-cel, our lead program, is an autologous, fully human CD19-targeting CAR T-cell product candidate that is designed for potency and…View ↗
We are currently focused on advancing our neuroimmunology CAR T franchise, which includes evaluating miv-cel in stiff person syndrome, or…View ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
−$41.9MView ↗
8-K, filed May 18, 2026
On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the…View ↗
Competes with Roche Holding, AbbVie, Johnson & Johnson, Bristol Myers Squibb, Novartis, Cabaletta Bio, and Cartesian Therapeutics
10-K for FY2025, filed Mar 26, 2026Companies developing biologics and other modalities include Roche Holding AG (currently markets Rituxan (rituximab), which is used for a…View ↗
Loading...